Navigation Links
Pluromed, Inc. Signs Agreement with Boston Scientific
Date:10/8/2009

Boston Scientific to distribute Pluromed's BackStop™ device, a rapid phase transition gel used in the treatment of Kidney Stones.

Woburn, Massachusetts (PRWEB) October 9, 2009 -- Pluromed, Inc. has announced that it has entered into an alliance with Boston Scientific Corporation (NYSE: BSX) regarding Pluromed's BackStop™ product, a device used in ureteroscopic kidney stone management procedures. Boston Scientific has acquired the worldwide distribution rights to BackStop. The financial terms of the agreement were not disclosed.

Kidney stone disease is estimated to affect millions of people worldwide. A common method of treating these stones is intracorporeal lithotripsy where the stones are fragmented using a laser or other energy modality in a minimally invasive procedure. Backstop™ is based on Pluromed's proprietary Rapid Transition Polymers™ (RTP™) that are liquid at low temperature and transition to a gel at body temperature; the transition is reversible via cooling and the gel is completely dissolvable. The BackStop gel forms a plug above the stones in the ureter and is designed to prevent stone migration during the procedure. After stone fragmentation is complete, the gel is dissolved with saline and exits the body. The BackStop product offers the potential to reduce operating time and complexity, and improve "stone free" rates for patients.

"We are very pleased to work with with Boston Scientific," said John Merhige, Pluromed's Vice President of Market Development. "BSC is the market leader with the resources and expertise to get the BackStop product into the hands of urologists." The BackStop device is approved for sale in Europe, Canada and the United States.

Jean-Marie Vogel, Pluromed's CEO, said, "This alliance represents an important event in the evolution of Pluromed. The proceeds from the agreement allow us to further invest in growing our core cardiovascular business, and with Boston Scientific distributing the BackStop product, we anticipate a successful launch and ongoing growth."

Pluromed and Boston Scientific will be working closely on integrating the BackStop product into BSC's systems in anticipation of the worldwide product launch.


About Pluromed, Inc.
Pluromed, Inc., Woburn, Massachusetts, founded in 2003, is pioneering the use of atraumatic gel plugs to improve the safety, efficacy and economics of medical interventions. These products address a broad surgery market that includes cardiac and vascular surgery, prostate, kidney and liver surgery, plastic/reconstructive surgery, trauma/battlefield applications and the treatment of kidney stones. They are based on the Company's patented rapid phase transition polymer technology; Pluromed Rapid Transition Polymers™ (RTP™) are liquid at low temperature and quickly transition to a high viscosity gel at body temperature. For more information, please visit www.pluromed.com

About Boston Scientific Corporation
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com

###

Read the full story at http://www.prweb.com/releases/2009/10/prweb3011074.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. SEO Consultant Top Rank Web Designs Gives Away 250 Free Websites
2. /R E P E A T -- DiagnoCure signs distribution agreement in the UK for its colorectal cancer test/
3. DiagnoCure signs distribution agreement in the UK for its colorectal cancer test
4. AdaptaVan, LLC Signs Two New Dealers: Company's Wheelchair Accessible Vans Now Available in North Carolina and Missouri
5. The MED Group Signs Preferred Supplier Agreement for Masimo SET(R) Pulse Oximetry Solutions
6. Rapid Fire Marketing Signs 5 Year Agreement
7. Osseon Signs International Distribution Agreement With MBA Incorporado
8. New device finds early signs of eye disease in preemies
9. GENova Biotherapeutics signs LOI with Korean university for stem cell research and patents sharing
10. GENova Biotherapeutics signs engagement agreement with PacificWave Partners Limited
11. Haemonetics Signs Comprehensive Agreement with Blood Centers of America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... MN (PRWEB) , ... February 24, 2017 , ... ... of its newly designed TaskMate Go. Core benefits and advantages built into the ... and a stylish, functional look and feel. Ability to gain the benefits embedded ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald ... officially announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, ... (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the Ohio University ...
(Date:2/24/2017)... ... ... The narrative in “ Signal 8: An Australian Paramedic’s Story ” (published by ... Schanssema describes the tragedies he saw, as well as his struggles with grief and ... unsure of the career path he wanted to take, found fulfillment in a career ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President and CEO ... year. Dyer started as the Chairman of the Management Committee when IFN was ... corporation including the recruitment of investor/owners and development of the business plan. He ...
(Date:2/23/2017)... TX (PRWEB) , ... February 23, 2017 , ... ... announced an official 2017 partnership with The Jensie Gran Fondo of Marin. For ... and UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... -- Physician General Dr. Rachel Levine and ... Smith commended South Central EMS today for their ... a life-saving overdose reversal drug. The recognition event also ... overdose survivor who was saved due to the administration ... part of fighting the opioid epidemic is making sure ...
(Date:2/24/2017)... 2017 Report analyzes the worldwide markets for Endodontic ... for the US, Canada , ... Asia-Pacific , Latin America , and ... the period 2015 through 2022. Also, a six-year historic analysis ... derived from primary and secondary research. Company profiles are primarily ...
(Date:2/24/2017)... Feb. 23, 2017 Non-alcoholic steatohepataitis ... the various drugs being developed for the ... the drugs that are in various phases ... pipeline focuses on novel pharmacologic drugs & ... cell therapies, recombinant proteins and RNA-based therapeutics, ...
Breaking Medicine Technology: